|
PXL/HO/Cir-080/2023-24 Date: 26.11.2023
Hyderabad
Subject:Bangalorechapterof“CapacityBuildingProgrammeon“ImportanceofQualityCompliance&Patient Safety – Industry Practices & Regulatory Expectations” on 15.Dec.2023 (Friday) at The CapitolHotel,Bangalore.
Members are aware that Pharmexcil has been conducting the Capacity Building Program on “Importance ofQualityCompliance&PatientSafety–IndustryPractices&RegulatoryExpectations”across the country at major pharma tocreateawarenessonQualityculture&uplifttheirunderstandingof Regulatory,GMP,and Quality&Safetynorms.
Weareproposingtohostthe similar program in Bangalore on 15th December 2023 (Friday) at The Capitol Hotel, Bangalore -560001
|
Bangalorechapter of CapacityBuildingProgram
“ImportanceofQualityCompliance&PatientSafety”
(IndustryPractices&RegulatoryExpectations)
|
|
Date &Time:
|
15th December 2023(Friday)
9.30am-4.30pm
|
|
Venue
|
The Capitol Hotel, NO. 3,RajBhavanRoad,Bangalore–560001, Karnataka
|
|
RegistrationLink
|
https://forms.gle/yCNHfN6UoSqeYNR66
|
|
Agenda
|
Enclosed
|
|
TargetAudience
|
-
Pharma Entrepreneurs
-
Pharma manufacturers including Production,Quality Control, Quality Assurance& Regulatory AffairsTeam
-
Biotech companies
-
API,Excipientsmanufacturers&Rawmaterialsuppliers &
-
TestingLabs
|
|
ParticipationFee
|
Rs.500/-perperson
BankDetails:
NameoftheAccount:PHARMACEUTICALSEXPORTPROMOTIONCOUNCILOFINDIA
TypeofAccount:CURRENT
AccountNo:510131000001693& IFSCCode:UBIN0805220
BankName&Address:UNION BANKOFINDIA,S.R.NAGARBRANCH,HYDERABAD4.)PHARMEXCILGSTNo's:36AADCP4643C1ZO(Telangana)
|
Member companies are requested to register your participation through theGoogle formlatest by12thDecember 2023 and actively participate in this full day Program and make it a grand success. We areconfident that the topics by eminent speakers in the technical session would greatly benefit all theparticipants.
For any additional information, members write to Mr.Mogan babu (bochennai@pharmexcil.com, & Ph.No:98414 08923).
Withregards,
Udaya Bhaskar
Director General
Encl: Agenda
|
